I agree all you have said in principle. On the other hand, if one looks the grand thing of DCVax trial data release from other angle, yes the quietness from the company may "kill" share price for a while such as no show in SNO (just a bag), but it actually shows strength, resolve and in effect imminent nature of news release as the company readily takes the pain of no showing, meaning journal publication may be really at the gate of letting go. And the bag, although not significant as someone had overthought over it, it's a way of advertisement: the company is well and just wait.
It also shows strength (not yet reflected on price yet) because the price has gone down so low that has reflected the price of "the worst case scenario, ie, only some subgroups are significant", a reasonable and average person would think the price now is very attractive, and will buy or add.
The only problem I see at the present in terms of softness in share price is that Island boys and vulture funds still have not had enough to "de-risk" by selling a portion of their legendary, almost freely collected shares (from converting warrants). These guys have no commitment, having not done (or never in their intention to do any) in-depth DD yet, no guts and no resources to "make the market" in any way, as they are a bunch of loose, selfish vultures who happened to all converge to nwbo a long time ago to exploit the worst situation years ago. In the process, collected huge piles of "free" warrants.
Nonetheless, they too will immediately switch from sell to buy as long as the market has a definite sign from the company: yes DCVax-L is indeed a go to FDA desk, either from journal publication, or else in official PR.
Trust me, in terms of reading tea leaves, or probing around either in a legal way or not, these vultures are much better at it than a few frequent tea leaf readers and overthinking posters on this board.
Fortunately things will not work that way. Relieved we are now in journal peer reviewing process, relieved we know from our DDs both primary and key secondary endpoints will be met significantly.
So I take the low price at present in stride, adding more or not.
GLTA!
